©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2018; 10(10): 290-292
Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.290
Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.290
Inhibiting focal adhesion kinase: A potential target for enhancing therapeutic efficacy in colorectal cancer therapy
Keun-Yeong Jeong, Division of Research and Development, Metimedi Pharmaceuticals, Incheon 22006, South Korea
Author contributions: Jeong KY conceived the study and drafted the manuscript; this author approved the final version of the article.
Conflict-of-interest statement: This author has no conflict of interest to declare.
Correspondence to: Keun-Yeong Jeong, PhD, SVP, Head of R and D, Division of Research and Development, Metimedi Pharmaceuticals, R and D Division, Metimedi Pharmaceuticals Co., 263, Central-ro, Yeonsu-Gu, Incheon 22006, South Korea. alvirus@naver.com
Telephone: +82-32-2050541 Fax: +82-32-2050542
Received: July 17, 2018
Peer-review started: July 17, 2018
First decision: August 2, 2018
Revised: August 16, 2018
Accepted: August 27, 2018
Article in press: August 28, 2018
Published online: October 15, 2018
Processing time: 90 Days and 10.2 Hours
Peer-review started: July 17, 2018
First decision: August 2, 2018
Revised: August 16, 2018
Accepted: August 27, 2018
Article in press: August 28, 2018
Published online: October 15, 2018
Processing time: 90 Days and 10.2 Hours
Core Tip
Core tip: Despite ongoing development in treatment for colorectal cancer (CRC), effective markers for treatment of CRC have not been elucidated. FAK association with various kinases for progression and invasion of CRC has recently gained attention. The possibility for this association is accounted that FAK is interactions with integrins, growth factor receptors, and adjacent kinase domain. Targeting FAK is possible to explain the mechanism at the upstream level by which can mediate the expression of various survival signaling and inhibition of onco-suppressor genes as well as inducing migration and invasion of the CRC cells. Therefore, FAK could be a prognostic marker and a potential candidate target for CRC therapies.